Table 1.
Baseline information and clinical features of the study subjects. PMI: Post Mortem Interval; Braak NFT stage: Braak neurofibrillary tangle stage; Braak Aβ stage: Braak amyloid beta plaque stage.
| Control | PD | PDD | DLB | AD | P | |
|---|---|---|---|---|---|---|
| Participants | 10 | 10 | 8 | 10 | 27 | |
| Male/Female | 6/4 | 7/3 | 7/1 | 5/5 | 13/14 | NA |
| Age | 83±2 | 78±2 | 77±3 | 81±2 | 82±2 | NA |
| PMI (h) | 18.8±5 | 16.0±3.2 | 10.8±1.6 | 18.0±3.7 | 10.6±1 | NA |
| Brain weight (g) | 1326±60 | 1299±40 | 1346±41 | 1273±38 | 1127±47 | NA |
| Onset | 65±3 | 60±3 | 66±4 | 71±2 | NA | |
| Progression | 14±1 | 16±3 | 14±3 | 10±1 | NA | |
| Braak NFT stage | Stage 0 :1 | Stage I :5 | Stage I :3 | Stage I :7 | Stage V :13 | * |
| Stage I :2 | Stage II :2 | Stage II :2 | Stage II :2 | stage VI :14 | ||
| Stage II :4 | Stage III :3 | Stage III :3 | Stage V :1 | |||
| Stage III :3 | ||||||
| Braak Aβ stage | All normal | Normal :3 | Normal :1 | Normal :1 | All stage C | NA |
| Stage A :1 | Stage A :2 | Stage A :1 | ||||
| Stage B :2 | Stage B :1 | Stage B :2 | ||||
| Stage C :5 | Stage C :4 | Stage C :6 | ||||
| L-Dopa response | Yes: 9 | Yes: 6 | Yes: 9 | |||
| Modest:1 | Modest:2 | Modest:1 |
*
indicates p < 0.05 vs. the controls.